Target intelligence / Profile preview

Gonadotropin-releasing hormone 1 receptor (GnRH1R)

Target
GnRH1R
Molecular classification
G protein-coupled receptor (GPCR), Receptor, Rhodopsin-like, class A GPCR
01

Overview

The gonadotropin-releasing hormone 1 receptor (GnRH1R) is a seven-transmembrane G protein-coupled receptor located primarily on pituitary gonadotrope cells, as well as extrapituitary sites including reproductive and some cancer tissues[1][4][6]. It mediates the physiological actions of GnRH—a decapeptide released by the hypothalamus—that regulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), playing a pivotal role in the control of reproduction[4][6][7][9]. Structurally, GnRH1R is notable for lacking the cytoplasmic C-terminal tail present in most class A GPCRs, leading to unique receptor activation and ligand-binding properties[1][2][3]. Pharmacologically, both agonists and antagonists for GnRH1R are widely used in reproductive medicine, hormone-dependent cancer therapy, and the management of diseases like endometriosis and infertility[3][5][6].

Other names
GnRH receptorGnRHRLuteinizing hormone-releasing hormone receptor (LHRHR)Gonadotrophin-releasing hormone receptorType I GnRH receptor
02

Mechanism of action

Agonists stimulate GnRH1R, causing receptor-mediated signaling and, with continued exposure, receptor downregulation and suppression of gonadotropin secretion. Antagonists block GnRH1R, inhibiting gonadotropin release and lowering sex steroid levels.

03

Biological functions

Signal transductionRegulation of gonadotropin hormone synthesis and secretionCentral control of mammalian reproductionModulation of the phosphatidylinositol-calcium second messenger systemActivation of protein phosphorylation cascades
04

Disease associations

Endocrine disordersHormone-responsive cancers (breast, ovary, prostate)InfertilityEndometriosisOther reproductive system diseases
05

Safety considerations

Risk of hypogonadism and bone loss due to sustained suppression of sex steroidsCardiovascular risk with long-term therapyHot flashes and other menopause-like symptoms in both genders when receiving antagonists or high-dose agonists
06

Interacting drugs

Elagolix (antagonist)

1 more in the full profile.

07

Biomarkers

Expression of GnRH receptor in tumors for cancer therapyCirculating gonadotropin hormone levels (FSH, LH) to monitor efficacy

Beyond the preview

Go deeper on Gonadotropin-releasing hormone 1 receptor (GnRH1R).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gonadotropin-releasing hormone 1 receptor (GnRH1R).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call